Literature DB >> 1993841

Tumor necrosis factor-alpha inhibits the competence signal delivered by HIV to normal B cells.

J F Delfraissy1, C Wallon, F Boue, F Barresinoussi, P Galanaud.   

Abstract

Polyclonal B cell activation is commonly observed in HIV-infected patients. The coordinate delivery of a number of signals is required for B cell response. This work was designed to better define the role of HIV in the first steps of normal human B cells activation. We show that the infectious virus or recombinant envelope proteins can render B cells responsive to the growth-promoting effect of several T cell-derived IL, IL-2, IL-4, and low m.w. (12-kDa) BCGF. HIV acts in the absence of monocytes and on different populations of B cells. The competence signal can be provided by recombinant gp160 envelope protein. CD4 molecule is not involved in the interaction of HIV with B cells. In addition, we demonstrate that tumor necrosis factor alpha has no promoting activity when B cells are preactivated by HIV and it can suppress the response of HIV-preactivated B cells to IL-2, IL-4, and 12-kDa BCGF. Thus, the HIV envelope can deliver an early signal to normal B cells and modulate B cell response to physiologic signals. The possible relevance of this phenomenon to the immune defect observed in HIV patients is discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1993841

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  2 in total

1.  Viral hijacking of mitochondrial lysyl-tRNA synthetase.

Authors:  Monika Kaminska; Vyacheslav Shalak; Mathilde Francin; Marc Mirande
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

2.  HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals.

Authors:  S Moir; A Malaspina; K M Ogwaro; E T Donoghue; C W Hallahan; L A Ehler; S Liu; J Adelsberger; R Lapointe; P Hwu; M Baseler; J M Orenstein; T W Chun; J A Mican; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.